ArticleTrends in biotechnology2026
Engineered probiotics block arsenite absorption in the gastrointestinal tract.
Article in Trends in biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From codon optimization to AI-guided sequence design for engineered biological functions.Molecular therapy. Nucleic acids · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chronic exposure to arsenite in food and water is a major global health concern, yet no practical strategies exist to prevent ingested arsenite from entering the body through the gastrointestinal tract. Here, we engineered Escherichia coli Nissle 1917 (EcN) to sense and sequester arsenite in situ, creating a probiotic-based approach to reduce host absorption of arsenite. The system involved an arsenite-responsive genetic toggle switch that activated chelator expression upon exposure; after arsenite was removed, it sustained output under biostatic conditions but shut off during active cell division. We also engineered a nontoxic, high-affinity arsenite-binding protein as the chelator. The resulting strain efficiently removed arsenite in vitro while maintaining robust growth. A mass-transfer model guided in vivo dosing, and mouse studies showed that engineered EcN reduced arsenite entry into the bloodstream and promoted its fecal elimination. These findings support the conclusion that this engineered probiotic approach is promising for addressing toxic pollutants in the diet.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.